KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with limited treatment options.
• Approximately 5-10% of PDAC cases feature wild-type KRAS, presenting unique molecular alterations.
• These rare alterations include gene fusions (ALK, ROS1, NTRK, RET, FGFR, NRG1) and germline DNA repair gene mutations.

Purpose of the Study:

• To review the prevalence, molecular characteristics, and clinical impact of gene fusions, amplifications, and mutations in PDAC.
• To focus on the wild-type KRAS subgroup and their susceptibility to targeted therapies.
• To highlight the importance of comprehensive genomic profiling for personalized treatment strategies.

Main Methods:

• Literature review integrating current evidence on PDAC molecular alterations.
• Analysis of clinical trial data and case reports on targeted therapy efficacy.
• Focus on fusion detection and germline mutation testing in PDAC patients.

Main Results:

• Gene fusions and mutations in wild-type KRAS PDAC patients can predict response to targeted therapies.
• FDA-approved drugs like selpercatinib, larotrectinib, and repotrectinib target specific gene fusions.
• Zenocutuzumab shows promise for NRG1 fusion-positive PDAC; germline mutations may indicate sensitivity to PARP inhibitors or platinum agents.

Conclusions:

• Comprehensive genomic profiling is crucial for identifying PDAC patients eligible for precision medicine.
• Targeted therapies and specific drug classes (e.g., PARP inhibitors) offer new treatment avenues for specific PDAC molecular subtypes.
• Identifying rare genetic alterations in PDAC can significantly improve patient outcomes through tailored therapeutic approaches.